Prognostic DNA methylation biomarkers in ovarian cancer
- PMID: 16675572
- DOI: 10.1158/1078-0432.CCR-05-1551
Prognostic DNA methylation biomarkers in ovarian cancer
Abstract
Purpose: Aberrant DNA methylation, now recognized as a contributing factor to neoplasia, often shows definitive gene/sequence preferences unique to specific cancer types. Correspondingly, distinct combinations of methylated loci can function as biomarkers for numerous clinical correlates of ovarian and other cancers.
Experimental design: We used a microarray approach to identify methylated loci prognostic for reduced progression-free survival (PFS) in advanced ovarian cancer patients. Two data set classification algorithms, Significance Analysis of Microarray and Prediction Analysis of Microarray, successfully identified 220 candidate PFS-discriminatory methylated loci. Of those, 112 were found capable of predicting PFS with 95% accuracy, by Prediction Analysis of Microarray, using an independent set of 40 advanced ovarian tumors (from 20 short-PFS and 20 long-PFS patients, respectively). Additionally, we showed the use of these predictive loci using two bioinformatics machine-learning algorithms, Support Vector Machine and Multilayer Perceptron.
Conclusion: In this report, we show that highly prognostic DNA methylation biomarkers can be successfully identified and characterized, using previously unused, rigorous classifying algorithms. Such ovarian cancer biomarkers represent a promising approach for the assessment and management of this devastating disease.
Similar articles
-
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers.Clin Cancer Res. 2002 Jul;8(7):2246-52. Clin Cancer Res. 2002. PMID: 12114427
-
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.Clin Cancer Res. 2008 Aug 15;14(16):5198-208. doi: 10.1158/1078-0432.CCR-08-0196. Clin Cancer Res. 2008. PMID: 18698038
-
Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease.Mol Cancer Res. 2007 Feb;5(2):153-63. doi: 10.1158/1541-7786.MCR-06-0034. Mol Cancer Res. 2007. PMID: 17314273
-
DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment.Gynecol Oncol. 2008 Apr;109(1):129-39. doi: 10.1016/j.ygyno.2007.12.017. Epub 2008 Jan 29. Gynecol Oncol. 2008. PMID: 18234305 Review.
-
Profiling studies in ovarian cancer: a review.Oncologist. 2007 Aug;12(8):960-6. doi: 10.1634/theoncologist.12-8-960. Oncologist. 2007. PMID: 17766655 Review.
Cited by
-
Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.Lab Invest. 2010 Mar;90(3):414-25. doi: 10.1038/labinvest.2009.138. Epub 2010 Jan 11. Lab Invest. 2010. PMID: 20065949 Free PMC article.
-
HOX genes in ovarian cancer.J Ovarian Res. 2011 Sep 9;4:16. doi: 10.1186/1757-2215-4-16. J Ovarian Res. 2011. PMID: 21906307 Free PMC article.
-
Enriched transcription factor binding sites in hypermethylated gene promoters in drug resistant cancer cells.Bioinformatics. 2008 Aug 15;24(16):1745-8. doi: 10.1093/bioinformatics/btn256. Epub 2008 Jun 6. Bioinformatics. 2008. PMID: 18540022 Free PMC article.
-
Computational Analysis of High-Dimensional DNA Methylation Data for Cancer Prognosis.J Comput Biol. 2022 Aug;29(8):769-781. doi: 10.1089/cmb.2022.0002. Epub 2022 Jun 6. J Comput Biol. 2022. PMID: 35671506 Free PMC article. Review.
-
Deconvolution of the gene expression profiles of valuable banked blood specimens for studying the prognostic values of altered peripheral immune cell proportions in cancer patients.PLoS One. 2014 Jun 24;9(6):e100934. doi: 10.1371/journal.pone.0100934. eCollection 2014. PLoS One. 2014. PMID: 24959668 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical